Brain mechanisms underlying apathy.

apathy cognitive neuroscience decision making effort goal-directed behaviour motivation reward

Journal

Journal of neurology, neurosurgery, and psychiatry
ISSN: 1468-330X
Titre abrégé: J Neurol Neurosurg Psychiatry
Pays: England
ID NLM: 2985191R

Informations de publication

Date de publication:
03 2019
Historique:
received: 10 07 2018
revised: 13 09 2018
accepted: 24 09 2018
pubmed: 28 10 2018
medline: 18 12 2019
entrez: 28 10 2018
Statut: ppublish

Résumé

The past few decades have seen growing interest in the neuropsychiatric syndrome of apathy, conceptualised as a loss of motivation manifesting as a reduction of goal-directed behaviour. Apathy occurs frequently, and with substantial impact on quality of life, in a broad range of neurological and psychiatric conditions. Apathy is also consistently associated with neuroimaging changes in specific medial frontal cortex and subcortical structures, suggesting that disruption of a common systems-level mechanism may underlie its development, irrespective of the condition that causes it. In parallel with this growing recognition of the clinical importance of apathy, significant advances have been made in understanding normal motivated behaviour in humans and animals. These developments have occurred at several different conceptual levels, from work linking neural structures and neuromodulatory systems to specific aspects of motivated behaviour, to higher order computational models that aim to unite these findings within frameworks for normal goal-directed behaviour. In this review we develop a conceptual framework for understanding pathological apathy based on this current understanding of normal motivated behaviour. We first introduce prominent theories of motivated behaviour-which often involves sequences of actions towards a goal that needs to be maintained across time. Next, we outline the behavioural effects of disrupting these processes in animal models, highlighting the specific effects of these manipulations on different components of motivated behaviour. Finally, we relate these findings to clinical apathy, demonstrating the homologies between this basic neuroscience work and emerging behavioural and physiological evidence from patient studies of this syndrome.

Identifiants

pubmed: 30366958
pii: jnnp-2018-318265
doi: 10.1136/jnnp-2018-318265
pmc: PMC6518466
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

302-312

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 206330/Z/17/Z
Pays : United Kingdom

Informations de copyright

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Brain. 2013 May;136(Pt 5):1568-77
pubmed: 23543483
Schizophr Bull. 2014 Mar;40 Suppl 2:S107-16
pubmed: 24375459
Lancet Neurol. 2015 May;14(5):518-31
pubmed: 25895932
Neurosci Biobehav Rev. 2016 Oct;69:381-401
pubmed: 27527825
Neuropsychopharmacology. 2010 Jan;35(1):48-69
pubmed: 19776734
Prog Neurobiol. 1980;14(2-3):69-97
pubmed: 6999537
Cereb Cortex. 2009 Oct;19(10):2240-7
pubmed: 19131436
Curr Biol. 2018 May 21;28(10):1561-1569.e3
pubmed: 29731299
Expert Opin Pharmacother. 2016 Aug;17(11):1453-61
pubmed: 27322571
Biol Psychiatry. 2011 Mar 1;69(5):424-31
pubmed: 21168124
Cereb Cortex. 2016 Feb;26(2):807-819
pubmed: 26564255
J Neurol Neurosurg Psychiatry. 2016 Mar;87(3):311-8
pubmed: 25934016
Proc Natl Acad Sci U S A. 2017 Aug 29;114(35):E7395-E7404
pubmed: 28808037
Nat Neurosci. 2009 Jul;12(7):939-45
pubmed: 19503087
Neurodegener Dis. 2016;16(5-6):352-6
pubmed: 27229348
Int Psychogeriatr. 2015 Jun;27(6):903-23
pubmed: 25355282
Brain. 2016 Oct;139(Pt 10):2706-2721
pubmed: 27452600
Dement Geriatr Cogn Disord. 2005;20(2-3):140-4
pubmed: 16020942
Nat Neurosci. 2016 Sep 27;19(10):1280-5
pubmed: 27669988
Science. 2004 Apr 16;304(5669):452-4
pubmed: 15087550
J Neurol Neurosurg Psychiatry. 2018 Apr;89(4):389-396
pubmed: 29066518
Cereb Cortex. 2006 Jul;16(7):916-28
pubmed: 16207933
Curr Opin Neurobiol. 2012 Dec;22(6):1027-38
pubmed: 22766486
Neuron. 2014 Sep 3;83(5):1019-39
pubmed: 25189208
Front Neurosci. 2011 Jun 21;5:81
pubmed: 21734862
Front Neurosci. 2017 Jun 06;11:316
pubmed: 28634438
Trends Cogn Sci. 2012 Feb;16(2):122-8
pubmed: 22226543
Neurosci Biobehav Rev. 2013 Nov;37(9 Pt A):2015-25
pubmed: 23583616
J Neuropsychiatry Clin Neurosci. 1991 Summer;3(3):243-54
pubmed: 1821241
Brain. 2016 May;139(Pt 5):1325-47
pubmed: 27189581
Eur Psychiatry. 2009 Mar;24(2):98-104
pubmed: 19201579
Schizophr Bull. 2015 Mar;41(2):503-12
pubmed: 25053653
Neuron. 2014 Jun 4;82(5):950-65
pubmed: 24908481
Cortex. 2013 May;49(5):1292-303
pubmed: 22721958
Cortex. 2015 Jan;62:119-57
pubmed: 24439664
Neuropsychologia. 2018 Sep;118(Pt B):54-67
pubmed: 28689673
Psychopharmacology (Berl). 2007 Apr;191(3):391-431
pubmed: 17072591
Mov Disord. 2009 Nov 15;24(15):2175-86
pubmed: 19768724
Neurobiol Learn Mem. 2016 Sep;133:233-256
pubmed: 27427327
Nat Neurosci. 2005 Dec;8(12):1704-11
pubmed: 16286932
J Neurol Neurosurg Psychiatry. 2014 Jun;85(6):668-74
pubmed: 24218528
Brain. 2018 Nov 1;141(11):3193-3210
pubmed: 30346491
Science. 2003 Nov 14;302(5648):1181-5
pubmed: 14615530
Stroke. 2009 Oct;40(10):3299-307
pubmed: 19713543
Brain. 2018 May 1;141(5):1455-1469
pubmed: 29672668
Nat Rev Neurosci. 2016 Mar;17(3):183-95
pubmed: 26865020
Schizophr Res. 2010 May;118(1-3):154-61
pubmed: 20005675
Nat Neurosci. 2018 Jun;21(6):787-793
pubmed: 29760524
Behav Brain Res. 1994 Dec 15;65(2):221-9
pubmed: 7718155
J Neurosci. 2002 Dec 15;22(24):10996-1003
pubmed: 12486195
Nat Neurosci. 2016 Jan;19(1):117-26
pubmed: 26595651
Sci Rep. 2018 Mar 1;8(1):3843
pubmed: 29497060
J Neurosci. 2016 Jun 22;36(25):6623-33
pubmed: 27335396
Annu Rev Neurosci. 2011;34:333-59
pubmed: 21456961
Psychol Rev. 2015 Jan;122(1):54-83
pubmed: 25437491
Neurology. 2013 Nov 5;81(19):1674-80
pubmed: 24107869
Cogn Affect Behav Neurosci. 2013 Dec;13(4):814-29
pubmed: 23712666
J Neurosci. 2014 Apr 23;34(17):5918-26
pubmed: 24760851
Neuron. 2012 Nov 8;76(3):470-85
pubmed: 23141060

Auteurs

Campbell Le Heron (C)

Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK campbell.leheron@ndcn.ox.ac.uk.
Department of Experimental Psychology, University of Oxford, Oxford, UK.
New Zealand Brain Research Institute, Christchurch, New Zealand.

Clay B Holroyd (CB)

Department of Psychology, University of Victoria, Victoria, British Columbia, Canada.

John Salamone (J)

Department of Psychological Sciences, University of Connecticut, Storrs, Connecticut, USA.

Masud Husain (M)

Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
Department of Experimental Psychology, University of Oxford, Oxford, UK.
Division of Clinical Neurology, John Radcliffe Hospital, Oxford University Hospitals Trust, Oxford, UK.
Wellcome Trust Centre for Integrative Neuroimaging, Oxford, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH